References
- 1
Cahill G F.
Starvation in man.
Clin Endocrinol Metab.
1976;
5
397-415
- 2
Kalra S P, Dube M G, Pu S, Xu B, Horvath T L, Kalra P S.
Interacting appetite-regulating pathways in the hypothalamic regulation of body weight.
Endocr Rev.
1999;
20
68-100
- 3
Broberger C, Hokfelt T.
Hypothalamic and vagal neuropeptide circuitries regulating food intake.
Physiol Behav.
2001;
74
669-682
- 4
Williams G, Bing C, Cai X J, Harrold J A, King P J, Liu X H.
The hypothalamus and the control of energy homeostasis: Different circuits, different
purposes.
Physiol Behav.
2001;
74
683-701
- 5
Zander M, Madsbad S, Madsen J L, Holst J J.
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity,
and beta-cell function in type 2 diabetes: A parallel-group study.
Lancet.
2002;
359
824-830
- 6
Larsen P J, Tang-Christensen M, Holst J J, Orskov C.
Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides
in the rat hypothalamus and brainstem.
Neuroscience.
1997;
77
257-270
- 7
Turton M D, O’Shea D, Gunn I, Beak S A, Edwards C M, Meeran K. et al .
A role for glucagon-like peptide-1 in the central regulation of feeding.
Nature.
1996;
379
69-72
- 8
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K.
Ghrelin is a growth-hormone-releasing acylated peptide from stomach.
Nature.
1999;
402
656-660
- 9
Korbonits M, Kojima M, Kangawa K, Grossman A B.
Presence of ghrelin in normal and adenomatous human pituitary.
Endocrine.
2001;
14
101-104
- 10
Tschop M, Smiley D L, Heiman M L.
Ghrelin induces adiposity in rodents.
Nature.
2000;
407
908-913
- 11
Wren A M, Small C J, Abbott C R, Dhillo W S, Seal l, Cohen M A. et al .
Ghrelin causes hyperphagia and obesity in rats.
Diabetes.
2001;
50
2540-2547
- 12
Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K. et al .
A role for ghrelin in the central regulation of feeding.
Nature.
2001;
409
194-198
- 13
Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K. et al .
Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide
that antagonizes leptin action through the activation of hypothalamic neuropeptide
Y/Y1 receptor pathway.
Diabetes.
2001;
50
227-232
- 14
Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I.
Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related
protein mRNA levels and body weight in rats.
Diabetes.
2001;
50
2438-2443
- 15
Tschop M, Weyer C, Tataranni P A, Devanarayan V, Ravussin E, Heiman M L.
Circulating ghrelin levels are decreased in human obesity.
Diabetes.
2001;
50
707-709
- 16
Hansen T K, Dall R, Hosoda H, Kojima M, Kangawa K, Christiansen J S. et al .
Weight loss increases circulating levels of ghrelin in human obesity.
Clin Endocrinol (Oxf).
2002;
56
203-206
- 17
Ukkola O, Ravussin E, Jacobson P, Snyder E E, Chagnon M, Sjostrom L. et al .
Mutations in the preproghrelin/ghrelin gene associated with obesity in humans.
J Clin Endocrinol Metab.
2001;
86
3996-3999
- 18
Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M. et al .
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia
and reduces insulin secretion in humans.
J Clin Endocrinol Metab.
2001;
86
5083-5086
C. B. Djuurhus, M.D.
Medical Department M (Endocrinology & Diabetes) · Aarhus University Hospital
Norrebrogade 42 - 44 · 8000 Aarhus C · Denmark ·
Phone: + 45 8949 2071
Fax: + 45 8949 2010
Email: cbd@dadlnet.dk
